These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Production of recombinant VP1-derived virus-like particles from novel human polyomaviruses in yeast. Norkiene M; Stonyte J; Ziogiene D; Mazeike E; Sasnauskas K; Gedvilaite A BMC Biotechnol; 2015 Aug; 15():68. PubMed ID: 26239840 [TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the carboxyl-terminal region of the SV40 major capsid protein VP1. Yokoyama N; Kawano MA; Tsukamoto H; Enomoto T; Inoue T; Takahashi RU; Nakanishi A; Imai T; Wada T; Handa H J Biochem; 2007 Feb; 141(2):279-86. PubMed ID: 17283011 [TBL] [Abstract][Full Text] [Related]
10. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500 [TBL] [Abstract][Full Text] [Related]
11. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. Boura E; Liebl D; Spísek R; Fric J; Marek M; Stokrová J; Holán V; Forstová J FEBS Lett; 2005 Dec; 579(29):6549-58. PubMed ID: 16298367 [TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration. Fric J; Marek M; Hrusková V; Holán V; Forstová J Vaccine; 2008 Jun; 26(26):3242-51. PubMed ID: 18468739 [TBL] [Abstract][Full Text] [Related]
13. Size and position of truncations in the carboxy-terminal region of major capsid protein VP1 of hamster polyomavirus expressed in yeast determine its assembly capacity. Gedvilaite A; Aleksaite E; Staniulis J; Ulrich R; Sasnauskas K Arch Virol; 2006 Sep; 151(9):1811-25. PubMed ID: 16575481 [TBL] [Abstract][Full Text] [Related]
14. Generation of virus-like particles consisting of the major capsid protein VP1 of goose hemorrhagic polyomavirus and their application in serological tests. Zielonka A; Gedvilaite A; Ulrich R; Lüschow D; Sasnauskas K; Müller H; Johne R Virus Res; 2006 Sep; 120(1-2):128-37. PubMed ID: 16780983 [TBL] [Abstract][Full Text] [Related]
15. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974 [TBL] [Abstract][Full Text] [Related]
16. Production and biomedical applications of virus-like particles derived from polyomaviruses. Teunissen EA; de Raad M; Mastrobattista E J Control Release; 2013 Nov; 172(1):305-321. PubMed ID: 23999392 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Trichodysplasia Spinulosa-Associated Polyomavirus Capsid Protein as a New Carrier for Construction of Chimeric Virus-Like Particles Harboring Foreign Epitopes. Gedvilaite A; Kucinskaite-Kodze I; Lasickiene R; Timinskas A; Vaitiekaite A; Ziogiene D; Zvirbliene A Viruses; 2015 Jul; 7(8):4204-29. PubMed ID: 26230706 [TBL] [Abstract][Full Text] [Related]
18. Point mutation in calcium-binding domain of mouse polyomavirus VP1 protein does not prevent virus-like particle formation, but changes VP1 interactions with Saccharomyces cerevisiae cell structures. Adamec T; Palková Z; Velková K; Stokrová J; Forstová J FEMS Yeast Res; 2005 Feb; 5(4-5):331-40. PubMed ID: 15691738 [TBL] [Abstract][Full Text] [Related]